Aripiprazole

PBAC's latest decision on Aripiprazole: Recommended (2025). Considered for Treatment of schizophrenia in adults. The drug is also TGA-registered for maintenance treatment to prevent recurrence of manic or mixed episodes of bipolar I disorder in adult patients as monotherapy, though the PBAC submission focused on schizophrenia.

Eligible population

Adults with schizophrenia requiring long-acting injectable aripiprazole treatment.

Therapy area

Mental health

Line of therapy

Any

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

aripiprazole once-monthly modified release injection vial kit

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Submission history

• Jul 2014: Recommended with restriction · Authority Required
• Jul 2018: Recommended with restriction · Authority Required
• Dec 2024: Recommended with restriction · Authority Required
• Jul 2025: Recommended · Authority Required

Similar precedents

• Paliperidone
  similarity 0.76
• Cariprazine
  similarity 0.72
• Brexpiprazole
  similarity 0.68
• Paliperidone palmitate
  similarity 0.65
• Clozapine
  similarity 0.64
• Lurasidone hydrochloride
  similarity 0.64